Effects of full-fat and fermented dairy products on cardiometabolic disease:Food is more than the sum of its parts by Astrup, Arne et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Effects of full-fat and fermented dairy products on cardiometabolic disease
Food is more than the sum of its parts
Astrup, Arne; Geiker, Nina Rica Wium; Magkos, Faidon
Published in:
Advances in Nutrition
DOI:
10.1093/advances/nmz069
Publication date:
2019
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY-NC
Citation for published version (APA):
Astrup, A., Geiker, N. R. W., & Magkos, F. (2019). Effects of full-fat and fermented dairy products on
cardiometabolic disease: Food is more than the sum of its parts. Advances in Nutrition, 10(5), 924S-930S.
https://doi.org/10.1093/advances/nmz069
Download date: 09. Oct. 2020
SUPPLEMENT
Effects of Full-Fat and Fermented Dairy Products
on Cardiometabolic Disease: Food Is More Than
the Sum of Its Parts
Arne Astrup,1 Nina Rica Wium Geiker,2 and Faidon Magkos2
1Department of Nutrition, Exercise, and Sports, Faculty of Science, University of Copenhagen, Nørre Campus, Copenhagen, Denmark; and 2Department of
Nutrition, Exercise, and Sports, Faculty of Science, University of Copenhagen, Frederiksberg Campus, Frederiksberg, Denmark
ABSTRACT
Current dietary recommendations to limit consumption of saturated fat are largely based on early nutrition studies demonstrating a direct link
between dietary saturated fat, elevated blood cholesterol levels, and increased risk of cardiovascular disease. As full-fat dairy products are rich
in saturated fat, these dietary guidelines recommend consumption of fat-free or low-fat dairy products in place of full-fat dairy. However, dairy
products vary greatly in both their nutrient content and their bioactive ingredients, and research increasingly highlights the importance of focusing
on whole foods (i.e., the food matrix) as opposed to single nutrients, such as saturated fat. In fact, the weight of evidence from recent large and
well-controlled studies, systematic reviews, and meta-analyses of both observational studies and randomized controlled trials indicates that full-fat
dairy products, particularly yogurt and cheese, do not exert the detrimental effects on insulin sensitivity, blood lipid profile, and blood pressure
as previously predicted on the basis of their sodium and saturated fat contents; they do not increase cardiometabolic disease risk and may in fact
protect against cardiovascular disease and type 2 diabetes. Although more research is warranted to adjust for possible confounding factors and
to better understand the mechanisms of action of dairy products on health outcomes, it becomes increasingly clear that the recommendation to
restrict dietary saturated fat to reduce risk of cardiometabolic disease is getting outdated. Therefore, the suggestion to restrict or eliminate full-fat
dairy from the dietmay not be the optimal strategy for reducing cardiometabolic disease risk and should be re-evaluated in light of recent evidence.
Adv Nutr 2019;10:924S–930S.
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Introduction
In the United States, dairy products, including cheese, dairy
desserts, and milk (low-fat and whole), are among the top
contributors of saturated fat in the diet (1). Current US
dietary guidelines (2015–2020) (2), supported by the con-
clusions of the European Food Safety Authority (EFSA) (3),
highlight the importance of reducing intake of saturated fat
for optimizing cardiometabolic health. Similar conclusions
have been reached by the WHO, which recommends that
saturated fat contributes <10% of total energy intake (4, 5).
The EFSA further recommends keeping saturated fat intake
“as low as possible.” This advice is based predominantly
on observational nutrition studies during the 1960s and
1970s that showed a direct association between saturated
fat consumption, raised blood cholesterol concentrations,
and increased risk of cardiovascular disease (CVD) (6, 7)
but also early clinical trials of replacement of saturated
fat by polyunsaturated fat (8). As full-fat dairy products
have a relatively high saturated fat content, current dietary
guidelines recommend consumption of fat-free or low-fat
dairy products in place of full-fat dairy.
However, there are many weaknesses in the evidence
and conceptual views linking saturated fat to CVD. First,
saturated fat consists of several different fatty acids (chain
lengths from 4 to 24 carbon atoms) with completely different
physicochemical properties and, subsequently, biological
effects in relation to CVD risk (9, 10). Second, the food
matrix in which the fatty acids exist in the diet may be
more important for the effect on CVD than the absolute
content of the food in saturated fatty acids (11); the same
may be true even for unsaturated trans fatty acids (12).
Last but not least, the effect of dietary saturated fat on
blood lipid profile (13) and CVD risk (14) depends on
the comparator macronutrient, for example, unsaturated fat
(and whether it is monounsaturated or polyunsaturated) or
carbohydrate (and whether it is refined or not). Inability to
account for some or most of these confounding factors may
be responsible for the fact that the dietary advice to simply
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decrease total fat intake, particularly saturated fat intake, has
been proven to be largely unsuccessful in reducing CVD risk
(15). Clearly, this implies we are missing some important
links of the chain leading from saturated fat to CVD, and
we should thus start looking into the health effects of dietary
saturated fat from a different perspective.
Saturated Fat and CVD
In contrast to current dietary recommendations, much of the
evidence from prospective cohort studies and randomized
trials over the past 10 y challenges the advice to reduce
saturated fat intake for reducing CVD risk. Rather, it
raises the question of whether it is prudent to restrict
intake of certain foods, such as full-fat dairy products,
solely based on their high saturated fat content. A meta-
analysis of prospective cohort studies (3–12 studies for
each association) demonstrated that, when comparing high
with low intakes of saturated fat, there is no convincing
evidence of an association between dietary saturated fat and
all-cause mortality, CVD, coronary heart disease (CHD),
ischemic stroke, or type 2 diabetes (T2D) (12). However,
the evidence and methodologies among the studies analyzed
are inconsistent. Importantly, the definition of “low-fat” and
“high-fat” dairy products varies considerably among studies
(0%–3.5% and 4%–80% of total food calories, respectively),
and most studies do not provide information on the total
fat content of the experimental diets, making interpretation
of the results difficult. These potential confounders need
to be controlled for in future trials. An earlier meta-
analysis of 21 prospective studies with 347,747 subjects also
found no significant evidence that dietary saturated fat is
associated with increased risk of CHD, stroke, or CVD
(16). Interestingly, an inverse association of saturated fat
intake with hemorrhagic stroke, but not ischemic stroke, was
reported in 2 of the included studies. No association between
saturated fat and stroke was found in 6 other studies. The
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relation of saturated fat intake with hemorrhagic, but not
ischemic stroke, may be caused by differing biological effects
of saturated fatty acids in relation to the pathophysiology of
different types of stroke. Examination of these 2 disease states
as distinct study end points may thus be important for future
research.
Biomarkers of fatty acid intake have also been used to
examine the association between saturated fat and CVD.
A systematic review and meta-analysis that included 17
observational studies of fatty acid biomarkers found no clear
evidence of differences in CHD risk between the highest
and lowest tertiles of saturated fat intake (17). Clinical trials
have also failed to consistently find evidence that dietary
saturated fat increases CHD risk or that replacing saturated
fat with polyunsaturated fat reduces CHD risk (18, 19),
despite observational studies reporting that substitution of
5% of daily calories from dairy fat with polyunsaturated
fat (mainly from plants) is associated with a 24% reduction
in CVD (20). A recent meta-analysis of randomized con-
trolled trials concluded that replacing saturated fatty acids
with mostly n–6 polyunsaturated fatty acids is unlikely to
reduce CHD events, CHD mortality, or total mortality and
provided evidence that the benefits reported in earlier meta-
analyses are due to the inclusion of inadequately controlled
trials (21).
Research increasingly highlights the importance of fo-
cusing on whole foods (i.e., the food matrix), as opposed
to single nutrients, such as saturated fat. A food product is
more than the sum of its individual components. Each food
has a complex physical and nutritional structure, which can
influence the digestion, absorption, and bioactive nature of
the nutrients it contains and subsequently their biological
effects. This is especially true for full-fat dairy products. It
is therefore possible that the combined action of SCFAs,
protein, calcium, vitamin D, and probiotics present in the
matrix of some dairy foods results in powerful beneficial
health effects regardless of the saturated fat content. SCFAs,
for example, are known to independently affect lipid, glucose,
and cholesterol metabolism in various tissues (22, 23).
Likewise, probiotics found inmany fermented dairy products
(i.e., live microorganisms with biological activity) and their
interactions with the gutmicrobiome canmodulate the effect
of dairy consumption on cardiometabolic function (24).
Dairy and Cardiometabolic Disease
The findings of a recent large cohort study, which included
136,384 individuals from 21 countries and 5 continents,
clearly demonstrated that dairy consumption (predomi-
nantly milk and yogurt) is associated with lower risk of mor-
tality and major CVD events (25). Furthermore, a systematic
review of meta-analysis of prospective population studies
(26) and an earlier prospective cohort study (Whitehall
II) (27) have also found an inverse or neutral relationship
between intake of dairy products and CVD. In addition,
Soedamah-Muthu et al. (28) performed ameta-analysis of 17
prospective cohort studies and found no association between
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intake of dairy and CHD risk, regardless of fat content,
but a possible inverse association with overall CVD risk.
For every 200-mL increase in milk consumption, there was
a 6% reduction in CVD (28). The same research group
performed another meta-analysis and found that both total
dairy consumption and low-fat dairy consumption were
associated with reduced risk of hypertension (29). A small
trial in 22 sedentary adult women observed a decrease in
systolic blood pressure and improvements in markers of
arterial function after 4 wk of milk protein supplementation
(30). These results indicate that a beneficial effect of dairy on
the risk of developing CVDmay bemodified by nutritive and
nonnutritive components other than fat (see also “Biological
Mechanisms”).
Qin et al. (31) also performed a meta-analysis of 22
prospective cohort studies that examined the association
between consumption of dairy products and CVD risk.
Again, results showed an inverse association between dairy
consumption (mainly low-fat but also cheese) and overall risk
of CVD and stroke but no association between intake of dairy
and risk of CHD (31). Guo et al. (32), in their meta-analysis
of 29 cohort studies with almost 1million participants, found
no associations between total dairy and milk intakes with
the health outcomes of mortality, CHD, or CVD but found
inverse associations for total fermented dairy (including sour
milk products, cheese, or yogurt) with mortality and CVD
risk. Finally, a newly published meta-analysis found that
dairy product consumption was inversely associated with
CVD (13 studies including 460,798 subjects), but subgroup
analyses revealed this association was significant only for
women (13% reduction in risk with high intake of dairy) but
not for men (33). It is unclear whether this sex difference is
mediated by differences in sex hormones or other factors.
The above lines notwithstanding, studies do suggest that
saturated fat from sources other than dairy (e.g., meat) may
have an adverse effect on CVD. In the Multi-Ethnic Study
of Atherosclerosis, substituting 2% of energy from meat-
saturated fat with dairy-saturated fat was associated with a
25% reduction in CVD risk (34). The latest meta-analysis of
prospective cohort studies on meat intake and CVD found
that the highest category of processed meat consumption
had a ∼21% greater risk of mortality from CVD (35). There
was, however, no association between total red meat intake,
white meat intake, and mortality from CVD (35). Given
that the same types of fat are found in processed meat and
nonprocessed meat, these results suggest something else in
the food processing may be responsible for the adverse effect
on CVD risk, but more research is needed in this area.
Similar to CVD, a systematic review and meta-analysis of
14 cohort studies reported an inverse relationship between
modest increases in dairy intake and T2D (36). A second
systematic review and dose-response meta-analysis of 17
cohort studies found a significant inverse, dose-dependent
association between intake of total dairy products, low-
fat dairy products, and cheese, and risk of T2D (37). In
a recent meta-analysis of 16 studies and 545,677 subjects,
high dairy consumption was associated with a 13% lower
risk of T2D among women, but no such protective effect
was found among men (33). Moreover, neither the European
Prospective Investigation into Cancer andNutrition (EPIC)–
InterAct Study—a nested cohort study in 8 European
countries (38)—nor the Rotterdam Study of adults ≥55 y of
age (39) found an association (whether positive or negative)
between consumption of dairy products (regardless of fat
content) and T2D.
Collectively, results from these recent studies, systematic
reviews, and meta-analyses do not provide convincing
evidence that saturated fat in dairy products increases risk
for cardiometabolic disease and instead suggest there may
be a potentially beneficial effect. However, more research is
warranted to adjust for possible confounding factors and to
assess the association between other types of dairy products
and health outcomes.
Fermented Dairy and Cardiometabolic Disease
Dairy products vary greatly in both their nutrient content and
their bioactive ingredients. The consumption of fermented
dairy, such as sour milk products, cheese, and yogurt, has
been found to have positive effects on body composition,
blood lipid profile, and cardiometabolic disease risk, which
may partly relate to microbiota metabolites, such as SCFAs.
Despite concerns related to saturated fat content, these
beneficial effects are observed regardless of whether the
fermented dairy product is low-fat or full-fat. Besides fat,
yogurt and cheese contain many other bioactive ingredients.
The process of fermentation leads to the structural change
of lipids and proteins in cheese and yogurt, which may be
responsible for some of their beneficial effects (40). The
more ripe the cheese, the greater the beneficial effects for
metabolic health, and this may be explained, in part, by the
end-products produced by gut bacteria that are powerful
enough to affect insulin sensitivity and CVD risk (41).
Several studies, including meta-analyses of observational
studies and randomized controlled trials, found no negative
effects of cheese consumption on body weight, metabolic
function, and CVD risk, despite its saturated fat and
sodium contents (42–44). In a highly publicized study on
2 large Swedish cohorts, high milk intake was associated—
unexpectedly—with increased mortality and hip fractures.
However, an observation that received far less attention is that
cheese and yogurt consumption was found to be protective
in reducing both mortality and the risk of hip fractures
(45). This finding, as well as others, suggests that future
research should distinguish between milk and fermented
dairy products (42, 43). We carried out a meta-analysis of
29 cohort studies, including the abovementioned Swedish
study, and found inverse associations of total fermented
dairy (sour milk products, yogurt, and cheese) consumption
with all-cause mortality and risk of CVD (32). For example,
CVD risk was reduced by ∼2% for every 10 g/d of cheese
consumption. Also, there was no evidence that low-fat
dairy products were better than full-fat dairy products.
All inverse associations between CVD and total fermented
dairy and cheese were attenuated in sensitivity analyses
926S Astrup et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/advances/article-abstract/10/5/924S/5569507 by D
anish R
egions user on 16 June 2020
when removing 1 large Swedish study, but no positive
association between fermented dairy and mortality or CVD
was found whatsoever (32). Also, in hypertensive patients,
higher consumption of yogurt was associated with a lower
risk of CVD, and the beneficial effect was more pronounced
among those following a healthier diet (46).
We conducted a randomized controlled trial to investigate
the mechanisms by which cheese does not increase, and
may actually decrease, CVD risk (47). Our hypothesis was
that since different dairy products have a different nutrient
composition, they would also differ in their effects on
blood lipid profile, which is a risk factor for CVD. A
total of 15 healthy young men consumed a control diet
or an isocaloric diet rich in milk or cheese for 14 d in
a crossover design. Compared with the milk-rich diet, the
cheese-rich diet led to significantly increased microbiota-
related metabolites butyrate, hippurate, and malonate (i.e.,
SCFAs), whereas the expected increase in LDL cholesterol
from cheese consumption did not occur (47). The control
diet provided ∼500 mg calcium/d, while the 2 test diets
provided ∼1700 mg calcium/d, and studies have suggested
that increasing dairy calcium intake by ∼1200 mg/d results
in an increase in fecal fat excretion by ∼5 g/d (48). This
may be related to the observed effects of the 2 diets
on lipid metabolism. Beneficial changes in total and LDL
cholesterol levels were highly correlated with the output
of some SCFAs in stool, suggesting that microbial and
lipid metabolism could be involved in the dairy-induced
effects on cardiometabolic risk factors (see also “Biological
Mechanisms”).
Regarding risk for T2D, a systematic review and meta-
analysis of randomized controlled trials found that increased
consumption of dairy products without energy restriction
did not result in significant changes in body weight or
body composition (49), which is of relevance given that
obesity is the major driver of the T2D epidemic (50). In fact,
inclusion of dairy products as part of a weight reduction diet
has been found to reduce body fat and/or increase fat-free
mass (49). In addition, a recent cross-sectional analysis of
114,682 adults found that yogurt and full-fat dairy intakes
have an inverse association with overweight and obesity; by
contrast, skimmed, semi-skimmed, and nonfermented dairy
had positive associations with overweight and obesity (51).
There is currently no evidence that low-fat fermented dairy is
better than full-fat fermented dairy in decreasing risk of T2D.
In fact, the opposite may be true: full-fat dairy appears to
be the most protective (32). An inverse association between
total dairy and yogurt intake and risk of T2D was reported
in a meta-analysis of 22 cohort studies with 579,832 subjects
(52). In addition, findings from theMaastricht Study showed
that, relative to lower intakes, high intakes of yogurt and
fermented dairy products were associated with lower odds
of newly diagnosed T2D and impaired glucose metabolism
by 25% to 40%, respectively (53). Large cohort studies in
the United States and Europe (Health Professionals Follow-
Up Study, Nurses’ Health Study I and II, and Maastricht
Study) as well as a recentmeta-analysis of cohort studies have
consistently found inverse associations between consump-
tion of fermented dairy products, including yogurt, cheese,
and fermented milk, and risk of T2D (36, 37, 53–55). On
the basis of 3 prospective cohort studies, a systematic review
by Drouin-Chartier et al. (26) found a neutral association
between consumption of regular- and high-fat dairy, milk,
and fermented dairy and risk of T2D but a protective effect
of low-fat dairy and yogurt (and maybe also cheese).
Biological Mechanisms
Relatively little research has evaluated the mechanisms by
which dairy products can modify risk for cardiometabolic
disease. Thewide variety of dairy products (e.g.,milk, yogurt,
cheese, cream, butter), the large variability in the type and
amount of their nutritive and nonnutritive components (e.g.,
calcium, fatty acids and other lipids, proteins, vitamins,
probiotics), and the potential influences of food production
characteristics, such as animal breeding and feeding, fermen-
tation, selection and cultivation of bacterial and yeast strains
(as fermentation starters), and homogenization, contribute
to the complexity of the biologically active content of dairy
that can affect downstreammolecular and signaling pathways
and, ultimately, cardiometabolic function (24).
Body weight, body composition, and fat deposition
Calcium supplementation in animal models of obesity
attenuates weight gain and hepatic fat accumulation, likely
by correcting signaling through leptin and glucagon-like
peptide 1, suppressing lipogeneses in the liver and adipose
tissue, reducing 1,25-dihydroxyvitamin D3 concentrations,
and altering gut microbiota (24). In human trials, calcium
supplementation has not been shown to have a significant
effect on body weight or body composition (56), whereas
consumption of milk and other dairy products decreases
body fat and increases or preserves lean mass, particularly
during weight loss (49, 56, 57), indicating a calcium-
independent mechanism. The protein in dairy (∼80% casein
and 20%whey) could be involved, perhaps via its stimulatory
effects on satiety, thermogenesis, and proteinosynthesis (58).
In longitudinal studies in free-living human subjects, low-
fat or full-fat milk or cheese has not been linked to weight
gain (i.e., they have a neutral effect), whereas yogurt has
been consistently found to attenuate weight gain (24),
thereby suggesting that fermentation products such as active
probiotics may be important for this effect.
Blood pressure and lipid profile
Calcium supplements (59) and casein-derived peptides (60)
may decrease systolic and diastolic blood pressure. Beneficial
effects on the arterial wall properties and blood pressure
have been observed in trials of nonfat and low-fat milk
consumption (61, 62) but not when full-fat milk is consumed
(63, 64), suggesting that differences in dairy fat type and
content may be relevant for the blood pressure–reducing
effect to manifest. Nevertheless, a randomized controlled
crossover trial in 36 participants, who completed three 3-wk
dietary periods in random order with a 2-wk washout
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in between, evaluated the effects of a standard Dietary
Approaches to Stop Hypertension (DASH) diet, which
included consumption of low-fat dairy and a higher-fat,
lower-carbohydrate modified DASH diet, which included
consumption of full-fat dairy, compared with a control diet
(65). Results indicated that consumption of full-fat dairy
in the modified higher-fat DASH diet was not associated
with an increase in blood pressure over the standard low-
fat DASH diet. There was also a beneficial effect of full-
fat dairy on triglyceride levels and LDL cholesterol particle
size, both of which are linked to CVD risk (65). The low-
fat DASH diet improved LDL cholesterol but worsened other
CVD risk factors, such as triglyceride and HDL cholesterol
levels (65). These findings indicate that full-fat dairy foods
could be incorporated in the DASH dietary pattern without
impairing its beneficial effects on blood pressure and may in
fact be superior to low-fat dairy in terms of the effects on
blood lipid profile. This is interesting because, according to
current dietary recommendations, saturated fat intake from
full-fat dairy would be expected to raise LDL cholesterol
concentration. However, randomized trials demonstrate a
large heterogeneity in this response depending on the type of
dairy product consumed. Compared with butter, cheese (66)
and whipping cream (67) lower total and LDL cholesterol
concentrations, despite otherwise identical dairy total and
saturated fat contents. The same is true when comparing
intake of saturated fat from milk and cheese with the
same type and amount of saturated fat from nondairy
sources (44). Furthermore, it has now become clear that
the effect of replacing saturated fat in the diet on blood
lipids and lipoproteins depends not only on the chain length
of the saturated fatty acid being replaced but also on the
replacement nutrient (13). These findings underscore the
complexity of the factors potentially contributing to the
observed health effects of dairy products. The systematic
and comprehensive assessment of these factors in future
studies will thus be important for better understanding of the
mechanisms of action of dairy on human health.
Insulin sensitivity and glucose homeostasis
Dairy products are good sources of protein, particularly
proteins rich in the branched-chain amino acids (comprising
∼21% of total dairy proteins) leucine, isoleucine, and valine,
which have been associated with insulin resistance and
T2D in epidemiological studies, supposedly by activating
important signaling pathways such as the mammalian target
of rapamycin (68, 69). However, more often than not
(70), observational studies and clinical trials identify dairy
products as a key component of a dietary pattern that
is inversely associated with features of insulin resistance,
such as lower postprandial glucose (i.e., improved glucose
tolerance), increased postprandial insulin (i.e., improved
β-cell function), and greater insulin-stimulated glucose
uptake (i.e., improved muscle insulin action) (71, 72). This
is in line with the protective effect of dairy consumption,
particularly yogurt, on the risk of developing T2D (52) but
alsowith theweight of evidence from epidemiological studies
and small clinical trials of dairy protein consumption and
improved glucose homeostasis in patients with T2D (73).
The importance of incretins (74) and inflammatory
mediators (24) in the health effects of dairy remains elusive.
Likewise, many other hypotheses have been put forth
regarding the potential mechanisms of action of dairy on the
basis of preliminary findings from studies in culture systems
and animal models, but none has been rigorously tested in
appropriate experimental settings in humans (24). Evidently,
research into the potential mechanisms responsible for the
effects of dairy products on cardiometabolic function and
subsequent disease risk is still in its infancy, and this is an
important area for future research.
Conclusions
The findings from the aforementioned studies are in line with
the consensus reached at an expert workshop in Gentofte,
Denmark, in 2016, which included the following statement:
“Current evidence does not support a positive association
between intake of dairy products and risk of CVD (i.e. stroke
and CHD) and T2D.” The workshop also concluded that
“different dairy structures and common processing methods
may enhance interactions between nutrients in the dairy
matrix, which may modify the metabolic effects of dairy
consumption” (23).
What becomes increasingly clear is that the recommen-
dation to restrict dietary saturated fat to reduce risk for
cardiometabolic disease is getting outdated. The weight of
evidence from recent meta-analyses of both observational
studies and randomized controlled trials indicates that full-
fat dairy products, particularly yogurt and cheese, do not
exert the detrimental effects on blood lipid profile and
blood pressure as previously predicted on the basis of their
sodium and saturated fat contents; they do not increase
cardiometabolic disease risk and may in fact protect against
CVD and T2D. Therefore, the suggestion to restrict or
eliminate full-fat dairy from the diet may not be the optimal
strategy for reducing cardiometabolic disease risk and should
be re-evaluated in light of recent evidence.
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